GLORIA

GEOMAR Library Ocean Research Information Access

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    In: Journal of Clinical Medicine, MDPI AG, Vol. 9, No. 8 ( 2020-08-14), p. 2642-
    Abstract: Mutations in the EGFR gene downstream signaling pathways may cause receptor-independent pathway activation, making tumors unresponsive to EGFR inhibitors. However, the clinical significance of RAS, PIK3CA or PTEN mutations in NSCLC is unclear. In this study, patients who were initially diagnosed with NSCLC or experienced recurrence after surgical resection were enrolled, and blood samples was collected. Ultra-deep sequencing analysis of cfDNA using Ion AmpliSeq Cancer Hotspot Panel v2 with Proton platforms was conducted. RAS/PIK3CA/PTEN mutations were frequently detected in cfDNA in stage IV NSCLC (58.1%), and a high proportion of the patients (47.8%) with mutations had bone metastases at diagnosis. The frequency of RAS/PIK3CA/PTEN mutations in patients with activating EGFR mutation was 61.7%. The median PFS for EGFR-TKIs was 15.1 months in patients without RAS/PIK3CA/PTEN mutations, and 19.9 months in patients with mutations (p = 0.549). For patients with activating EGFR mutations, the overall survival was longer in patients without RAS/PIK3CA/PTEN mutations (53.8 months vs. 27.4 months). For the multivariate analysis, RAS/PIK3CA/PTEN mutations were independent predictors of poor prognosis in patients with activating EGFR mutations. In conclusion, RAS, PIK3CA and PTEN mutations do not hamper EGFR-TKI treatment outcome; however, they predict a poor OS when activating EGFR mutations coexist.
    Type of Medium: Online Resource
    ISSN: 2077-0383
    Language: English
    Publisher: MDPI AG
    Publication Date: 2020
    detail.hit.zdb_id: 2662592-1
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
  • 2
    In: Electronics, MDPI AG, Vol. 8, No. 3 ( 2019-03-20), p. 338-
    Abstract: Today’s mobility management (MM) architectures, such as Mobile Internet Protocol (IP) and Proxy Mobile IP, feature integration of data and control planes, as well as centralized mobility control. In the existing architecture, however, the tight integration of the data and control planes can induce a non-optimal routing path, because data packets are delivered via a central mobility agent, such as Home Agent and Local Mobility Anchor. Furthermore, the centralized mobility control mechanism tends to increase traffic overhead due to the processing of both data and control packets at a central agent. To address these problems, a new Internet architecture for the future mobile network was proposed, named Mobile-Oriented Future Internet (MOFI). The MOFI architecture was mainly designed as follows: (1) separation of data and control planes for getting an optimal data path; (2) distributed identifier–locator mapping control for alleviating traffic overhead at a central agent. In this article, we investigate the validity of the MOFI architecture through implementation and experimentations over the European Union (EU)–Korea testbed network. For this purpose, the MOFI architecture is implemented using OpenFlow and Click Modular Router over a Linux platform, and then it is evaluated over the locally and internationally configured EU–Korea testbed network. In particular, we operate two realistic communication scenarios over the EU–Korea testbed network. From the experimentation results, we can see that the proposed MOFI architecture can not only provide the mobility management efficiently, but also support the backward compatibility for the current IP version 6 (IPv6) applications and an Internet Protocol network.
    Type of Medium: Online Resource
    ISSN: 2079-9292
    Language: English
    Publisher: MDPI AG
    Publication Date: 2019
    detail.hit.zdb_id: 2662127-7
    Location Call Number Limitation Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...